Long-term Follow-up and Monitoring

Long-term Follow-up - The Marathon Care

• Objective: Ensure lifelong well-being; monitor hormone therapy efficacy & safety.
• Schedule: Annually or as clinically indicated post-stabilization.
• Core Monitoring:
  • Hormone levels: Maintain in affirmed gender's physiologic range.
  • Metabolic profile: Lipids, glucose (HbA1c).
  • Bone Mineral Density (BMD): DEXA as per guidelines.
  • Cardiovascular health: Blood pressure.
  • Cancer screening: Relevant to natal organs & hormone exposure.
  • Mental & sexual well-being.

⭐ For transmasculine individuals on testosterone, monitor for erythrocytosis (↑hematocrit) due to supraphysiologic testosterone effects.

Transfeminine Monitoring - Estrogen's Watch

• Goal: Ensure estrogen efficacy & safety.
• Schedule:
  • 1st Year: Every 3 months.
  • Thereafter: Annually/biannually.
• Key Parameters:
  • Clinical: BP, weight, breast exam, VTE signs.
  • Labs: Estradiol (target 100-200 pg/mL), testosterone (<50 ng/dL), prolactin, LFTs, lipids, K+ (with spironolactone).
• Risk Management:
  • VTE: Counsel; oral estrogen ↑ risk.
  • Cardiovascular: Monitor BP, lipids.
  • Bone Health: DEXA if indicated (e.g., age >60, risk factors).
• Cancer Screening:
  • Breast: Mammography (cis-female guidelines, e.g., age 50 / 5-10 yrs estrogen if >40).
  • Prostate: Discuss PSA if prostate present.

⭐ Monitor prolactin; levels >100 ng/mL may suggest prolactinoma, requiring MRI or further evaluation.

Transmasculine Monitoring - Testosterone's Trail

• Primary Goals: Achieve desired virilization; maintain testosterone in physiologic male range.
• Baseline Assessment: CBC, LFTs, lipid profile, fasting glucose/HbA1c.
• Regular Follow-up (Every 3 months for 1st year, then 1-2 times annually):
  • Clinical Evaluation: BP, weight, acne, hair patterns (growth/loss), mood changes, libido, symptoms of androgen excess.
  • Laboratory Tests:
    • Serum testosterone (trough for injections). Target: physiologic male range.
    • Hematocrit/Hemoglobin: Monitor for erythrocytosis (Hct > 50-54%).
    • Lipid profile, LFTs (as indicated, e.g., annually or if risk factors).
  • Cancer Screening:
    • Cervical cytology (if cervix present) per standard guidelines.
    • Breast cancer screening (individualized based on residual breast tissue/risk factors).

⭐ Erythrocytosis (Hematocrit > 50-54%) is a significant potential adverse effect of testosterone therapy, warranting dose adjustment or phlebotomy.

Mental & Sexual Health - Mind & Joy Check

• Mental Well-being:
  • Screen for anxiety (e.g., GAD-7), depression (e.g., PHQ-9), suicidality.
  • Evaluate social support, discrimination impact.
  • Timely referral to mental health services.
• Sexual Function & Satisfaction:
  • Open discussion: libido, orgasm, pleasure.
  • Address fertility preservation, contraception, STIs.
  • Support positive body image & intimacy.
• Overall Joy & QoL:
  • Assess quality of life (QoL) regularly.
  • Encourage peer support & community connection.

  ⭐ Mental health comorbidities are common; proactive screening and support significantly improve outcomes in individuals undergoing gender transition.

Special Issues & Risks - Navigating Nuances

• Cardiovascular: Monitor BP, lipids, glucose.
• Bone Health: DEXA if risk factors (e.g., GnRH agonist use, low E/T).
• Cancer Screening: Based on organs present (prostate, cervix, breast).

  ⭐ Transfeminine individuals on estrogen: routine breast cancer screening (age >50, 5-10 yrs hormones).

• Mental Health: Ongoing support crucial.
• Fertility: Discuss preservation pre-treatment.
• Thromboembolism (VTE): Risk with estrogens (oral > transdermal).
• Sexual Health: Address concerns, STI prevention.

High‑Yield Points - ⚡ Biggest Takeaways

• Regular hormone monitoring is key to maintain desired levels and minimize side effects.
• Monitor for metabolic changes: lipids, glucose, and bone mineral density (BMD).
• Individualized cancer screening considers natal organs and hormone exposure.
• Assess cardiovascular risk factors regularly, especially with testosterone.
• Ongoing mental health support and screening for mood changes are vital.
• Trans women: monitor prolactin (high-dose estrogen/cyproterone).
• Trans men: monitor hematocrit/hemoglobin (testosterone effect).